Get the Stockscreener App
36.60
1.03%
-0.38
Terns Pharmaceuticals Inc stock is traded at $36.60, with a volume of 1.92M.
It is down -1.03% in the last 24 hours and down -14.73% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$36.98
Open:
$36.91
24h Volume:
1.92M
Relative Volume:
0.49
Market Cap:
$3.98B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-27.73
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+3.16%
1M Performance:
-14.73%
6M Performance:
+594.50%
1Y Performance:
+713.33%
1-Day Range:
$36.43
$38.24
1-Week Range:
$33.43
$38.37
52-Week Range:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
36.60 | 4.02B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Wall Street forecasts 42.31% upside to Terns Pharmaceuticals, Inc. (TERN) - MSN
Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN) - Yahoo Finance
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map - TechStock²
Terns Pharmaceuticals (NASDAQ:TERN) Trading Up 10.4%Should You Buy? - MarketBeat
Aug Patterns: Can Terns Pharmaceuticals Inc stock sustain institutional interestJuly 2025 Final Week & Consistent Profit Trade Alerts - Bộ Nội Vụ
J.P. Morgan: Terns Looks To Take Flight With TERN-701 In 2026 - Citeline News & Insights
William Blair reiterates Outperform rating on Terns Pharmaceuticals stock By Investing.com - Investing.com Canada
Terns Pharmaceuticals (TERN) Valuation After Encouraging TERN 701 CML Data And Capital Raise Powered Development Plans - Yahoo Finance
Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN) - Insider Monkey
Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3%Here's Why - MarketBeat
Assessing Terns Pharmaceuticals (TERN) Valuation After Recent Share Price Swings And Elevated Price To Book Ratio - Sahm
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Terns Pharmaceuticals (TERN) - The Globe and Mail
How Rhythm Pharmaceuticals, Inc. stock performs during market volatility - Улправда
Tern Pharmaceuticals (TERN) soars 630% on CML treatment best-in-class potential - MSN
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63 - MSN
Why Terns Pharmaceuticals Inc. stock could see breakout soonEarnings Beat & Consistent Return Investment Signals - ulpravda.ru
Why Terns Pharmaceuticals Inc. stock could be next big winnerEarnings Recap Summary & Daily Entry Point Trade Alerts - Улправда
Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative - Sahm
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Star Tribune - FinancialContent
Terns Pharmaceuticals CMO Kuriakose sells $44,552 in stock By Investing.com - Investing.com Australia
Terns Pharmaceuticals CMO Kuriakose sells $44,552 in stock - Investing.com
Terns Pharmaceuticals CEO Burroughs sells $2.7m in shares By Investing.com - Investing.com South Africa
Terns Pharmaceuticals CEO Burroughs sells $2.7m in shares - Investing.com
Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) Insider Sells 1,155 Shares of Stock - MarketBeat
With 53% Institutional Ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Is a Favorite Amongst the Big Guns - 富途牛牛
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential - Insider Monkey
Two new Terns hires receive 10-year stock options as hiring incentive - Stock Titan
Meet the 10 Market Stars Behind Millionaire-Making in 2025 - Insider Monkey
Terns Pharmaceuticals Earnings Notes - Trefis
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale - ts2.tech
Exchange Traded Concepts LLC Has $912,000 Position in Terns Pharmaceuticals, Inc. $TERN - MarketBeat
Terns Pharmaceuticals stock soars after leukemia drug delivers big early responses in tough-to-treat patients - MSN
Pharmaceutical Stocks To Follow TodayDecember 10th - MarketBeat
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Truist Securities maintains Terns Pharmaceuticals (TERN) buy recommendation - MSN
Terns Pharmaceuticals (TERN) Is Down 7.7% After Strong TERN-701 Phase 1 DataHas The Bull Case Changed? - Sahm
Jim Cramer highlights massive gains for Terns Pharmaceuticals shareholders - MSN
Terns Pharmaceuticals (TERN) Price Target Increased by 75.91% to 54.63 - Nasdaq
Will Terns Pharmaceuticals Inc. stock gain from government policies2025 Bull vs Bear & Weekly High Potential Alerts - moha.gov.vn
How Terns Pharmaceuticals Inc. stock performs in weak economyEarnings Performance Report & High Conviction Trade Alerts - Улправда
Is Terns Pharmaceuticals Inc. stock attractive for long term wealth buildingJobs Report & Target Return Focused Stock Picks - Улправда
Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders - Finviz
Terns Pharmaceuticals unveils promising phase 1 trial data - MSN
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):